Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
15-week phase 2 randomized double-blind placebo-controlled dose-ranging study of PF-06649751 as adjunct to levodopa in Parkinson's disease
2015-004912-39Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing PF-06649751 + levodopa (dose-ranging) with Placebo + levodopa (2 arms). Primary endpoint: Change from baseline in daily OFF time at Week 10. Started Feb 2016; status: terminated.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2015-004912-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004912-39.